China’s Innovent Biologics, Inc. (HKG: 1801) announced that the first participant has been dosed in the higher-dose cohort of a Phase II trial for mazdutide (IBI362), a dual agonist targeting glucagon-like peptide 1 receptor (GLP-1R) and glucagon receptor (GCGR), in Chinese adults with obesity. The study follows positive results from a lower-dose cohort, where mazdutide demonstrated an 11.6% mean body weight reduction.
Study Design and Objectives
The randomized, double-blind, placebo-controlled trial (NCT04904913) will enroll 80 participants with obesity (BMI ≥ 30 kg/m²) in a 3:1 ratio to receive 9.0 mg mazdutide or placebo weekly for 24 weeks. The primary endpoint is percentage change in body weight from baseline at week 24. The higher-dose cohort aims to evaluate efficacy and safety after prior low-dose data showed significant weight loss.
Mechanism and Collaboration
Mazdutide is a long-acting synthetic peptide derived from mammalian oxyntomodulin (OXM), designed for once-weekly dosing via a fatty acid side chain. Innovent licensed the drug from Eli Lilly and Company for development and potential commercialization in China. The partnership combines Innovent’s local expertise with Lilly’s global R&D capabilities in metabolic therapies.-Fineline Info & Tech
